Commonly used AML CAR targets such as CD33 and CD123, which are present in approximately 80–90% and 70–80% of AML patients, respectively, are also expressed on HSCs and on normal myeloid progenitor cells [20,21,22]. This evidence concerns the gene CD33 and acute myeloid leukemia.